Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Twist Bioscience CorporationNASDAQ: TWST

Gross Margin · Q4 FY2026 · quarter ended Sep 2026

Gross margin widens to 53.1%

Gross margin was 53.1% in Q4 FY2026, up 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 52.4%, up 1.7 pp year over year. Over 3 fiscal years it widened by 15.8 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2026 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
53.1%+0.3 pp QoQ
Last fiscal yearSep 2026
52.4%+1.7 pp YoY
LTMSep 2026
52.4%+1.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.8 pp——
1 year+1.7 pp——
3 years+15.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2026
52.4%
Year-over-year change
+1.7pp

Gross Margin vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 gross margin of 52.4% is the highest of the 2 companies compared; the peer median is 51.1%.
  • Its year-over-year change of +1.7 pp is the lowest of 2, against a peer median of +6.8 pp.
  • Over three fiscal years its change of +15.8 pp compares with a peer median of -9.8 pp.
TWST Competitors Peer median
Gross Margin for TWST and competitors
Company Period LTM level YoY 3-year change
TWSTTwist Bioscience CorporationLTM Sep 202652.4% +1.7 pp+15.8 pp
RGENRepligen CorporationLTM Jun 202651.1% +6.8 pp-9.8 pp
Peer median (excluding TWST) 51.1%+6.8 pp-9.8 pp

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue203.57M245.11M312.97M376.57M459.43M
Cost of Revenue119.33M155.38M179.63M185.57M218.63M
Gross Profit84.24M89.73M133.35M191M240.8M
Gross Margin41.4%36.6%42.6%50.7%52.4%
Research & Development120.31M106.89M90.85M80.29M71.84M
Selling, General & Admin212.95M189.74M218.4M246.98M301.22M
Operating Expenses319.01M306.89M354.18M327.26M380.26M
Depreciation & Amortization16.51M29.31M31.43M24.85M0
EBITDA(211.68M)(174.15M)(176.71M)(52.1M)(129.8M)
EBITDA Margin-104.0%-71.1%-56.5%-13.8%-28.3%
Operating Income(234.78M)(217.16M)(220.83M)(136.26M)(139.46M)
Operating Margin-115.3%-88.6%-70.6%-36.2%-30.4%
Interest Income3.06M14.37M15.34M11.36M8.8M
Interest Expense80K5K29K00
Other Income / Expenses6.5M13.69M12.67M59.31M8.85M
Income Before Tax(228.27M)(203.47M)(208.17M)(76.95M)(130.61M)
Pre-Tax Margin-112.1%-83.0%-66.5%-20.4%-28.4%
Income Tax Expense(10.41M)1.15M560K719K(406K)
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Net Margin-107.0%-83.5%-66.7%-20.6%-28.3%
EPS (Basic)(4.04)(3.60)(3.60)(1.30)(2.08)
EPS (Diluted)(4.04)(3.60)(3.60)(1.30)(2.08)
Weighted Avg Shares53.89M56.89M58.02M59.81M62.62M
Weighted Avg Shares (Diluted)53.89M56.89M58.02M59.81M62.62M

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.